Alnylam Pharmaceuticals Inc (ALNY)vsInhibrx Biosciences, Inc. (INBX)
ALNY
Alnylam Pharmaceuticals Inc
$291.37
-0.19%
HEALTHCARE · Cap: $39.26B
INBX
Inhibrx Biosciences, Inc.
$95.31
-4.65%
HEALTHCARE · Cap: $1.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 329663% more annual revenue ($4.29B vs $1.30M). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
INBX
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$291.37
$2072.01 discount
Margin of Safety
-64.3%
Fair Value
$49.90
Current Price
$95.31
$45.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : INBX
The strongest argument for INBX centers on Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Bear Case : INBX
The primary concerns for INBX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while INBX is a value play — different risk/reward profiles.
INBX carries more volatility with a beta of 3.32 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 20/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Inhibrx Biosciences, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?